7LGK

Crystal structure of soluble guanylate cyclase activator runcaciguat (BAY 1101042) bound to nostoc H-NOX domain


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.207 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.164 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

Hahn, M.G.Lampe, T.El Sheikh, S.Griebenow, N.Woltering, E.Schlemmer, K.H.Dietz, L.Gerisch, M.Wunder, F.Becker-Pelster, E.M.Mondritzki, T.Tinel, H.Knorr, A.Kern, A.Lang, D.Hueser, J.Schomber, T.Benardeau, A.Eitner, F.Truebel, H.Mittendorf, J.Kumar, V.van den Akker, F.Schaefer, M.Geiss, V.Sandner, P.Stasch, J.P.

(2021) J Med Chem 64: 5323-5344

  • DOI: 10.1021/acs.jmedchem.0c02154
  • Primary Citation of Related Structures:  
    7LGK

  • PubMed Abstract: 
  • Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis ...

    Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. The first generation of sGC activators like cinaciguat or ataciguat exhibited limitations and were discontinued. We overcame limitations of first-generation sGC activators and identified a new chemical class via high-throughput screening. The investigation of the structure-activity relationship allowed to improve potency and multiple solubility, permeability, metabolism, and drug-drug interactions parameters. This program resulted in the discovery of the oral sGC activator runcaciguat (compound 45 , BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy.


    Organizational Affiliation

    Institute of Pharmacy, University Halle-Wittenberg, 06120 Halle, Germany.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
H-NOX domain proteinA, B182Nostoc sp. PCC 7120 = FACHB-418Mutation(s): 0 
Gene Names: alr2278
UniProt
Find proteins for Q8YUQ7 (Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576))
Explore Q8YUQ7 
Go to UniProtKB:  Q8YUQ7
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.207 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.164 
  • Space Group: P 21 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 123.99α = 90
b = 123.99β = 90
c = 123.99γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
REFMACrefinement
PDB_EXTRACTdata extraction
XDSdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2021-05-05
    Type: Initial release
  • Version 1.1: 2021-05-26
    Changes: Database references